Home Daily Stock Opinions and Ratings ISHARES DOW JONES US MEDICAL DEV.(ETF) (IHI-N)

Trending stocks today

Royalty Pharma plc Comcast Corp Onity Group. Inc. Allstate CVS Health Corp Savaria Corp Jamieson Wellness Stella-Jones Inc. Tesla Inc CVS Health Corp Advanced Micro Devices Broadcom Mastercard Inc. Superior Plus Corp Omnicom Group GlaxoSmithKline PLC Leidos Holdings, Inc. Africa Oil Corp. International Petroleum Company Ecora Resources

ISHARES DOW JONES US MEDICAL DEV.(ETF) (IHI-N)

NEW AI Investor Insights
61 watching

NYSEARCA:IHI

59.61
0.45 (0.75%) 1d
Dec 13, 2024, 8:59 pm
0

Related posts

3 Best U.S. Healthcare ETFsOur Mega List of the Latest ETFs Mentioned on StockchaseSienna Senior Living, CVS Health and 12 of the Top the Healthcare Stocks to Buy
BUY

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI-N)

30/08/2022
ISHARES DOW JONES US MEDICAL DEV.(ETF)
Allan Tong’s Discover Picks IHI's MER is actually higher (at 0.39%) than the yield it pays (0.3%). Like the other names here, IHI trades at a low beta, 0.86 to be precise. So, if you're not buying this for income, what's the growth? Let's look at IHI's largest holdings. TMO offers diversity among lab testing, lab equipment and diagnostics and typically trades at a premium multiple. TMO was a hit in the Covid-testing days, but that stereotype has stuck with them. The company reported a strong quarter a month ago, but that didn't move the needle. TMO shares have been choppy but rangebound all year, but if Wall Street gets gospel on TMO, share should pop. The price target is 20% higher at $674. Read 3 Best U.S. Healthcare ETFs for our full analysis.
E.T.F.'s
Stockchase Discover
$50.540
Unknown
UnlockRating
BUY ON WEAKNESS

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI-N)

04/04/2022
ISHARES DOW JONES US MEDICAL DEV.(ETF)
Likes medical devices and health area as society ages. Would buy during a correcting. US and Europe have good healthcare stocks.
E.T.F.'s
Larry Berman CFA, CMT, CTA
$61.105
No
UnlockRating
BUY

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI-N)

03/08/2021
ISHARES DOW JONES US MEDICAL DEV.(ETF)

Happy to own this, outperforming XLV, for instance. It's diversified. ZUH is another option, because it covers pharmas, hospital management and other areas. IHI, as a hospital provider, is pretty good.

E.T.F.'s
John Hood
$63.490
Owned
UnlockRating
BUY

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI-N)

22/04/2021
ISHARES DOW JONES US MEDICAL DEV.(ETF)

Not overly bullish on healthcare as a whole, as its growth may be less attractive. Likes medical devices, with a built-in backlog due to Covid. He owns SYK. There should be a significant pickup in procedures over the next 2 years. SYK has strong earnings growth, near a 1-year high. Also look at IHI, the medical devices ETF, packed with companies leading the healthcare sector.

E.T.F.'s
David Burrows
$360.725
Unknown
UnlockRating
PARTIAL SELL

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI-N)

03/11/2020
ISHARES DOW JONES US MEDICAL DEV.(ETF)
This ETF has smashed it over the past 5 years. Medical devices are a hybrid of tech and healthcare, which he really likes. Problem is that market enthusiasm and growth are priced in here already (like the FAANGs). Take profits.
E.T.F.'s
Tyler Mordy
$307.020
Unknown
UnlockRating
BUY

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI-N)

08/04/2020
ISHARES DOW JONES US MEDICAL DEV.(ETF)
It specializes in medical devices and equipment. He has held this over a year and a half. He likes the diversification it offers. He is not sure which of the holdings are involved in manufacturing defibrillators.
E.T.F.'s
John Hood
$239.735
Owned
UnlockRating
DON'T BUY

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI-N)

25/02/2020
ISHARES DOW JONES US MEDICAL DEV.(ETF)
It's very nichy, though it offers good exposure to healthcare. It's a high-beta play on healthcare, biotech and medical devices. His main worry is uncertainty around the US election, namely Bernie Sanders. If he nationalizes medical care, then this ETF will suffer.
E.T.F.'s
Tyler Mordy
$256.900
Unknown
UnlockRating
BUY

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI-N)

27/12/2019
ISHARES DOW JONES US MEDICAL DEV.(ETF)
He likes medical devices a lot. The ETF looks good with reasonable MER. Once the rhetoric from the presidential campaign subsides, it’ll probably have more smooth sailing.
E.T.F.'s
Richard Croft
$264.960
No
UnlockRating
PAST TOP PICK

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI-N)

03/10/2019
ISHARES DOW JONES US MEDICAL DEV.(ETF)
(A Top Pick Oct 16/18, Up 16%) It continues to work. Everything is going right with this one. It is not a defensive name and while he likes it, he would not have more than a few percent of it in the market.
E.T.F.'s
Cameron Hurst
$241.940
No
UnlockRating
TOP PICK

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI-N)

03/10/2019
ISHARES DOW JONES US MEDICAL DEV.(ETF)
He loves it. It was flat over the last quarter. He is sticking with it.
E.T.F.'s
Cameron Hurst
$241.940
Owned
UnlockRating
PAST TOP PICK

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI-N)

13/09/2019
ISHARES DOW JONES US MEDICAL DEV.(ETF)

(A Top Pick Aug 15/18, Up 20%) A good way to play pharma without the litigation problems. For a Canadian one, it would be ZUH. Medical devices have done very well, and wish he had more.

E.T.F.'s
John Hood
$248.790
Owned
UnlockRating
TOP PICK

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI-N)

11/09/2019
ISHARES DOW JONES US MEDICAL DEV.(ETF)
A perennial favorite for him. Worldwide hospital spending, global spending and Type II diabetes on the rise all make this a good holding. It is fairly high beta, so if the market falls this will fall too. Yield 0.31%
E.T.F.'s
Cameron Hurst
$248.420
Owned
UnlockRating
TOP PICK

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI-N)

07/08/2019
ISHARES DOW JONES US MEDICAL DEV.(ETF)
The only area of healthcare he remains invested in. The demographics are creating tailwinds. An aging population and growing obesity is good for this. Good cash flow holdings and good diversification. Yield 0.32%
E.T.F.'s
Cameron Hurst
$241.305
Owned
UnlockRating
PAST TOP PICK

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI-N)

10/07/2019
ISHARES DOW JONES US MEDICAL DEV.(ETF)
(A Top Pick Jul 11/18, Up 19%) A great example of demographic and diabetes trends that has created huge growth in demand. A sad, but profitable story. Not a defensive stock and has beta with the market.
E.T.F.'s
Cameron Hurst
$243.330
Owned
UnlockRating
PAST TOP PICK

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI-N)

05/06/2019
ISHARES DOW JONES US MEDICAL DEV.(ETF)
(A Top Pick Jun 08/18, Up 11%) He continues to love holding this. Worldwide hospital spending continues to increase.
E.T.F.'s
Cameron Hurst
$228.090
Owned
UnlockRating
Showing 1 to 15 of 44 entries
Next PageNext Page

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI-N) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for ISHARES DOW JONES US MEDICAL DEV.(ETF) is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI-N) Frequently Asked Questions

What is ISHARES DOW JONES US MEDICAL DEV.(ETF) stock symbol?

ISHARES DOW JONES US MEDICAL DEV.(ETF) is a American stock, trading under the symbol IHI-N on the NYSE Arca (IHI). It is usually referred to as AMEX:IHI or IHI-N

Is ISHARES DOW JONES US MEDICAL DEV.(ETF) a buy or a sell?

In the last year, there was no coverage of ISHARES DOW JONES US MEDICAL DEV.(ETF) published on Stockchase.

Is ISHARES DOW JONES US MEDICAL DEV.(ETF) a good investment or a top pick?

ISHARES DOW JONES US MEDICAL DEV.(ETF) was recommended as a Top Pick by on . Read the latest stock experts ratings for ISHARES DOW JONES US MEDICAL DEV.(ETF).

Why is ISHARES DOW JONES US MEDICAL DEV.(ETF) stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is ISHARES DOW JONES US MEDICAL DEV.(ETF) worth watching?

0 stock analysts on Stockchase covered ISHARES DOW JONES US MEDICAL DEV.(ETF) In the last year. It is a trending stock that is worth watching.

What is ISHARES DOW JONES US MEDICAL DEV.(ETF) stock price?

On 2024-12-13, ISHARES DOW JONES US MEDICAL DEV.(ETF) (IHI-N) stock closed at a price of $59.61.

Your Watchlist

Add stocks to watchlist to monitor them daily and get important alerts.

Get Access To Watchlist

Latest Buy Signals

GSY-Tgoeasy
goeasy
$161.86
0.20 (0.12%)
LHX-NL3Harris Technologies
L3Harris Technologies
$223.12
-1.23 (-0.55%)
MGA-TMega Uranium
Mega Uranium
$0.35
0.00 (0.00%)
DC.A-TDundee Corp. (A)
Dundee Corp. (A)
$1.59
0.01 (0.63%)
SGD-XSnowline Gold
Snowline Gold
$5.11
0.02 (0.39%)
Advertising

Today's Top Picks

ECOR-TEcora Resources
Ecora Resources
$1.31
0.13 (9.03%)
IPCO-TInternational Petroleum Company
International Petroleum Company
$16.05
0.21 (1.29%)
AOI-TAfrica Oil Corp.
Africa Oil Corp.
$1.94
0.04 (2.02%)
LDOS-NLeidos Holdings, Inc.
Leidos Holdings, Inc.
$153.16
0.18 (0.12%)
GSK-NGlaxoSmithKline PLC
GlaxoSmithKline PLC
$33.95
-0.22 (-0.65%)

Popular Articles

Questrade Review: Pros & Cons of Trading with Questrade Canada (2021) Steady Eddys: 3 Stable Stocks Between Safety and Risk: 3 Safe and Gambling Stocks 3 Oversold Stocks to Take Advantage of 5 ETFs for Index Investing

Latest Sell Signals

III-TImperial Metals Corp
Imperial Metals Corp
$1.93
-0.07 (-3.76%)
IMG-TIamgold Corp
Iamgold Corp
$7.60
-0.31 (-4.25%)
PPTA-QPerpetua Resources
Perpetua Resources
$11.91
0.10 (0.83%)
DG-NDollar General Corp.
Dollar General Corp.
$76.94
-1.48 (-1.96%)
VRT-NVertiv Holdings
Vertiv Holdings
$125.78
0.74 (0.58%)

Most Recent Experts

Rule

Rick Rule

Rule Investment Medial

Stockchase

Stockchase Insights

5i Research

Pyle

Andrew Pyle

The Pyle Group, Scotia Wealth Mgt.

Panic-Proof (Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Buzzing

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Advertising
Advertising
logoTop pickslogoStockslogoRecentlogoWatchlist
© Stockchase Inc.